The LICL provides expertise in tumor immunology and advanced tools and know-how to analyze immune parameters in blood and tumor of cancer patients within the frame of basic, translational and clinical research projects. Its main objectives are to identify predictive factors of response to immunotherapy and define mechanisms of primary or acquired resistance in order to discover new therapeutic targets.
The platform welcomes projects from CRCL/CLB researchers/clinicians, academic labs and private companies
and offers collaborative support and services in:
Various modes of access to the platform are possible with preference for collaborative projects.
In the context of clinical trials, PI3 performs longitudinal immune monitoring studies on human blood to identify predictive factors
of response and define mechanisms of primary or acquired resistance
in orderto discover new immunotherapy targets.
The platform develops and provides advanced multiplex IF
staining and digital image analysis tools to assess the in situ
immune contexture of human tumors in tight collaboration
with the bio-pathology platforms.
Location : Cheney B 3rd floor
Interested by any approach/expertise offered by the platform for your research projects ?
Please contact us in order to define collectively the most appropriate experimental strategy to reach the objectives. Collaborative work is preferred but service provision possible.
